XXXX : potentially curable with intensive chemotherapy.

@entity1 @entity137 @entity295 @entity66 @entity3003 @entity900 @entity786 @entity2879 @entity6831 @entity1891 @entity995
BACKGROUND: @entity995 has been lethal in virtually all cases previously reported. We describe a series of 13 @entity1 treated with intensive chemotherapy, defined as the intention to include high-dose chemotherapy with autologous hematopoietic stem cell rescue. PROCEDURE: Induction chemotherapy generally included @entity1891 , @entity900 or @entity3003 , @entity786 , and @entity2879 . Hematopoietic stem cells typically were harvested after the first or second cycle of induction chemotherapy, usually from peripheral blood. High-dose chemotherapy regimens were thiotepa-based (n = 7) or melphalan and @entity786 (n = 3). RESULTS: Trilateral sites were pineal (n = 11) and suprasellar (n = 2); 7 @entity1 had localized (M-0) disease and six had @entity6831 (M-1+). Five @entity1 had @entity995 at original diagnosis of @entity995 ; eight later developed @entity66 at a median of 35 months (range 3-60 months) following diagnosis of @entity995 . One @entity1 died of @entity137 ( @entity295 and multi-organ system failure) during induction and three developed disease progression prior to high-dose chemotherapy. Nine @entity1 received high-dose chemotherapy at a median of 5 months (range 4-9) post-diagnosis of @entity66 . Five @entity1 survive event-free at a median of 77 months (range 36-104 months) and never received external beam radiation therapy. Four of seven @entity1 with M-0 disease survive event-free versus only one of six @entity1 with M-1+ disease. CONCLUSIONS: Intensive chemotherapy is potentially curative for some @entity1 with @entity995 , especially those with M-0 disease.
